| Ytd | 32.41% | |
| 1y | 50.68% |
| Open | 1.43 | Prev Close | 1.41 | Low | 1.37 | High | 1.55 | Mkt Cap | 22.75M |
| Vol | 127.50K | Avg Vol | 156.14K | EPS | -0.70 | P/E | -2.04 | Forward P/E | -0.02 |
| Beta | 0.29 | Short Ratio | 0.30 | Inst. Own | 2.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.34 | 200-d Avg | 1.23 | 1yr Est | 5.00 |
ALLR News
Here is how Allarity Therapeutics, Inc. (ALLR) and ANIXA BIOSCIENCES INC (ANIX) have performed compa
Allarity Therapeutics is now poised to run its DRP ® testing in-house in a CLIA-certified laboratory
Here is how Allarity Therapeutics, Inc. (ALLR) and Amgen (AMGN) have performed compared to their sec
Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP ® until A
Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript
Here is how Allarity Therapeutics, Inc. (ALLR) and Alterity Therapeutics Limited - Sponsored ADR (AT
Principal Investigator Kathleen N. Moore, M.D.
Here is how Allarity Therapeutics, Inc. (ALLR) and Bioventus (BVS) have performed compared to their
- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast T
TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDA
Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting
TARPON SPRINGS, Fla., April 27, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NA
Strengthened financial position through disciplined cost management, with a year-end 2025 cash posit
Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) is expected to be posting its results before
Allarity Therapeutics, Inc. (NASDAQ: ALLR - Get Free Report) was the recipient of a large decline in
Extends Company Cash Runway into Mid-2028 Financing Expected to Fund Completion of Phase 2 Ovarian C
Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Ce
This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's
Cardio Diagnostics (NASDAQ: CDIO - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Fr
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarte
On Thursday, 369 companies hit new 52-week lows.
On Wednesday, 311 stocks hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
Friday's session saw 225 companies set new 52-week lows.
On Thursday, 283 companies set new 52-week lows.
On Tuesday, 164 companies achieved new lows for the year.
During Wednesday's trading, 103 companies set new 52-week lows.
On Tuesday, 46 stocks hit new 52-week lows.
Wednesday saw 59 companies set new 52-week lows.
Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) shares gained 124% to $0.3325. Mobiquity Tech
On Wednesday, 129 stocks made new 52-week lows.
On Monday, 147 stocks made new 52-week lows.
During Friday's session, 149 stocks hit new 52-week lows.
During Thursday's session, 99 companies made new 52-week lows.
During Wednesday's trading, 123 companies set new 52-week lows.
On Friday, 127 companies set new 52-week lows.
During Thursday's trading, 110 companies set new 52-week lows.
On Wednesday, 220 stocks hit new 52-week lows.